Effect of laughter yoga on anxiety and depression in people with Parkinson’s disease: a randomized controlled trial Authors: Qingnv Xu, Xiaoyun Nian, Yuxin Pan, Lan Zhang, Suping Lin, Siyu Zheng, Chunxiu Xiao Published: 2025 ABSTRACT AbstractBackgroundThe large number of people with Parkinson’s disease (PD) with anxiety or depression in China is a cause of concern. Sustained aerobic exercise is a promising therapy for delaying motor disabilities in people with PD. Laughter yoga is an aerobic training program that has proven to be beneficial in affecting the mental and physical aspects of healthy individuals, but its effect on anxiety and depression in people with PD has not been studied in controlled trials. The aim of this study was to assess the effectiveness of laughter yoga on anxiety, depression, sleep quality, and quality of life in people with PD.MethodsA randomized controlled trial design was used in this study. Ninety-four participants were randomly divided into two groups: 47 in the control group and 47 in the laughter yoga group. All participants received disease-related health education. The intervention group performed laughter yoga exercises, which consisted of two team exercises and five autonomous exercises per week. Participants exercised 20 min per session for 8 weeks. The primary outcomes were the Hamilton Anxiety Scale (HAMA) and Hamilton Depression Scale (HAMD) scores. The secondary outcomes were Parkinson’s Disease Sleep Scale (PDSS) and Parkinson’s Disease Quality of Life Scale-39 (PDQ-39) scores.ResultsNinety-four participants were included in the study. At baseline, there were no significant differences between the groups in terms of any demographic, anthropometric, clinical, or outcome characteristics. After intervention, the HAMA and HAMD scores were significantly lower in the laughter yoga group than in the control group (P < 0.05). Additionally, the PDQ-39 score was significantly lower in the laughter yoga group than in the control group (P < 0.05). There was no significant difference in the PDSS scores between the laughter yoga and control groups (P > 0.05).ConclusionsThe study results indicate that laughter yoga is an effective intervention for reducing anxiety and depression symptoms and improving the quality of life in people with PD.Trial registrationThe trial was registered retrospectively on May 30, 2022 (ChiCTR2200060401).Supplementary InformationThe online version contains supplementary material available at 10.1186/s12906-025-05225-x.Keywords: Parkinson’s disease, Anxiety, Depression, Laughter yoga, Sleep, Quality of life Background Parkinson’s disease (PD) is a neurodegenerative disorder that affects approximately 7–10 million individuals worldwide, commonly middle-aged and older people [1]. Anxiety and depression are frequent nonmotor symptoms that can occur at all stages before and after PD diagnosis [2]. Anxiety and depression affect approximately 40–50% of people with PD, presenting mainly as insomnia, low mood, irritability, and paranoia [3]. One study has shown that anxiety and depression symptoms may affect the progression of motor symptoms and are correlated with decreased sleep quality and quality of life in people with PD [4]. Therefore, addressing anxiety and depression symptoms in people with PD is important. At present, interventions for people with PD with anxiety or depression are mainly carried out through drugs [5], exercise [6], cognitive behavioral therapy [7], and deep brain stimulation [8]. Exercise therapy is extremely popular because of its good efficacy, low cost, and minimal side effects in patients. An alternative modality, developed by Dr. M. Kataria, is a laughter exercise called laughter yoga [9]. Laughter yoga combines unconditional laughter and yogic breathing. In this activity, one laughs without relying on humor, jokes, or comedy, and laughter is simulated as a body exercise in a group. Kataria believes that fake and real laughter have the same effect on the body [10]. Laughter has a positive effect on the cardiovascular [11], endocrine [12], respiratory [13], and skeletal muscle systems [14], reduces cortisol levels, promotes serotonin secretion, contributes to the improvement of sleep quality, and alters the activity of dopamine and 5-hydroxytryptophan, which counteracts negative mood and reduces anxiety and depression [15]. Yoga-based breathing practices can positively impact mental health by improving individuals’ levels of depression, anxiety, stress, and fear (such as COVID-19 positive hospitalized patients) [16]. Laughter yoga does not require special training venues or professional yoga equipment, nor does it need to rely on professionals, and its movements are simple, safe, and low in intensity. Practitioners can learn and practice alone in a short time, the exercise cost is low, patient participation is high, and it is easy to adhere to. Previous studies have shown the positive effects of laughter yoga on mental aspects in those on maintenance hemodialysis [17] and patients with cancer [18]. It can reduce anxiety and depression symptoms and improve patients’ sleep quality and quality of life. To date, laughter yoga has been mainly used to improve general mood. However, there are few studies on its effect on specific diseases, and relevant research on people with PD is in the preliminary exploration stage [19]. Further intervention programs should be considered. No study has assessed anxiety and depression symptoms in individuals with PD undergoing a laughter yoga protocol. Therefore, the aim of this study was to evaluate the effects of laughter yoga on anxiety, depression, sleep quality, and quality of life in people with PD. We hypothesized that laughter yoga would decrease the symptoms of anxiety and depression and improve sleep quality and quality of life in people with PD. This study adopted a self-made laughter yoga exercise program suitable for people with PD to explore its efficacy in easing anxiety and depression, improving sleep quality, and improving the quality of life of these patients. Methods Study design and participants This was a single-blind randomized control trial in which people with PD with anxiety and depression were 1:1 randomized to an intervention group, receiving laughter yoga (LYG), or a control group, receiving usual care (CG). A nursing graduate student who did not participate in this study ensured random grouping employing the Research Randomizer website (https://www.randomizer.org). This study was approved by the Ethics Committee of Fujian Medical University Union Hospital, Fujian Province, China (2021KY180) in December 2021. people with PD who visited the Pingtan Branch of Fujian Medical University Union Hospital in Fujian Province were recruited, and a continuous sampling method was adopted. We followed CONSORT 2010 guidelines. The sample size was calculated using the formula used to compare the means of the two samples. Calculation formula: . The Class I and II error probabilities of the test set in this study were two-sided: α = 0.05, β = 0.10, =1.96, =1.282. Referring to a relevant intervention study [15], the standard deviation (=4.2) of the total scores of entries in the experimental group after intervention and mean difference (=5.7) of the total scores of entries in the experimental group after and before intervention were used to calculate the sample size (n1 = n2 = 40). Considering the 20% loss to follow-up rate in the study, 47 participants in the LYG and 94 participants in total were selected. Initially, 94 individuals from the hospital were selected. Eligibility criteria included: (a) the 2016 Chinese diagnostic criteria for PD are met [20], Unified Parkinson’s Disease Rating Scale (UPDRSUIII) score is < 30 points, and Modified Hoehn & Yahr grading scale is not higher than stage 3; (b) Hamilton Anxiety Scale (HAMA) score is ≥ 7 or Hamilton Depression Scale (HAMD) score is ≥ 8; (c) able to understand and cooperate with the completion of the intervention and related questionnaires; and (d) informed consent and voluntary participation in the research. Participants were excluded if they (a) had severe abnormalities in liver, kidney, heart, or lung function; (b) used medication for psychiatric disorders; (c) were receiving other anxiolytic or depression treatments; and (d) had participated in other similar studies in the previous 3 months. All participants provided written informed consent. Outcome measures Baseline measurements included patient demographics (sex, age, education level, current work status, marital status, mode of residence, per capita monthly household income, mode of payment for medical care, and number of falls in 1 year) and clinical disease information (disease duration, number of comorbidities, modified Hoehn and Yahr (H-Y) classification [21], Unified Parkinson’s Disease Rating Scale score (UPDRSIII) [22], and levodopa equivalent dosage). The primary outcome measures included scores on the Scales for Outcomes in the HAMA [23] (14 items, scores <7 indicate no anxiety symptoms; 7–14 suggest possible anxiety; 15–21 confirm anxiety; 22–28 indicate significant anxiety; ≥29 indicate severe anxiety) and HAMD [24] (7 sections, scores <7 indicate no depressive symptoms; 8–17 suggest possible depression; 18–25 confirm depression; >25 indicate severe depression) to assess anxiety and depression. These scales have been validated and are considered reliable tools. The secondary outcomes were Parkinson’s Disease Sleep Scale (PDSS) [25] (on a scale from 0 to 150, with higher scores indicating better sleep quality) and Parkinson’s Disease Quality of Life Scale-39 (PDQ-39) [26] scores (eight dimensions, 39 questions, with higher scores indicating lower quality of life). Interventions The intervention program of this study was developed based on the broaden-and-build theory [27], with reference to Dr. Kataria’s book “Laugh For No Reason” [28] and Zhang Lixin’s book “Laughter Movement” [29]. During the pre-study period, a research team was established and the content analysis method was used to summarize, analyze, compare, and summarize the elements of each intervention. Using literature analysis and expert meeting methods, we constructed an exercise intervention program for people with PD accompanied by anxiety or depression, and filmed the corresponding exercise videos. Eight participants were selected for the pre-test, which confirmed that the content of the program was scientific and reliable. The pre-test was feasible, safe, and targeted, and was acceptable to the participants with a good effect from the initial application. The study used claps and HO-HA (patient must make a “Ho! Ho! Ha! Ha! Ha!” sound from the abdomen) as a warm-up exercise, which led to eight laughter styles, namely ear rubbing and laughter, greeting laughter, rocking laughter, hot-soup laughter, bow-drawing laughter, laughter while counting on fingers, belly laughter, Maitreya Buddha laughter, and finally ended with breathing meditation. This study was conducted by a researcher and assistants. After a 1-week yoga course in a yoga studio, the researcher and assistants mastered the meditation breathing techniques and precautions required for laughter yoga. This allowed them to mobilize the experimental atmosphere and ensure the acceptance, compliance, and safety of the participants. The intervention program included an intervention form, intervention cycle, frequency and duration, intervention site, and exercise content (see Appendix 1 for details). The CG received the usual health education, including PD-related disease knowledge, medication knowledge, rehabilitation knowledge, and routine psychological support. The intervention group engaged in laughter yoga exercises that were based on health education. The duration of the intervention was 8 weeks. Participants performed group exercise (twice/week) and home-based autonomous exercise by watching a video (five times/week) for 20 min each time. Each session consisted of an intervention safety assessment before, during, and after the exercise, a warm-up exercise, simulated laughter, and some precautions. Statistical analysis Data were analyzed using SPSS version 26. The level for significance was P<0.05. Variables with normal distribution are reported as mean ± standard deviation and were analyzed using an independent-samples t-test; those with non-normal distribution are reported as median (25th–75th percentile) and were analyzed using the Wilcoxon signed-rank test and Mann-Whitney U test. Count data are reported as frequency and component ratios and were analyzed using the chi-square and Fisher’s exact tests. Results Ninety-four participants took part in this study. Of the 47 participants in the LYG, 44 participated in the intervention and completed post-intervention data collection. Of the 47 participants in the CG, 46 completed post-intervention data collection. The total dropout rate in this study was 4.26%, of which 6.38% and 2.13% were in the LYG and CG groups, respectively (Fig. 1). CONSORT flow chart of the study At baseline and post-intervention, there were no differences between the groups (LYG × CG) in any demographic or clinical disease characteristics (Appendix 2 and Appendix 3). At pre-intervention, the differences in HAMA and HAMD scores between the experimental and control groups were not significant; thus, the groups were comparable (Table 1). Meanwhile, there were no significant differences in the total PDSS and PDQ-39 scores, or the scores for each dimension, between the groups (Table 1). Table 1Comparison of outcomes between the groups at pre-interventionTests (mean ± SD)SUM (N = 94)LYG (n = 47)CG (n = 47)t P HAMA16.78 ± 4.116.72 ± 3.8516.83 ± 4.37−0.1250.901HAMD9.19 ± 4.469.04 ± 4.539.34 ± 4.43−0.3220.748PDSS118.6 ± 12.36118.81 ± 12.13118.57 ± 12.710.0910.927PDQ-3936.29 ± 10.9636.25 ± 10.7236.34 ± 11.41−0.3700.970Mobility5.72 ± 3.845.81 ± 3.715.63 ± 4.050.2120.832Activities of daily of living2.40 ± 2.762.17 ± 2.632.64 ± 2.91−0.8170.416Emotional well-being6.29 ± 2.616.38 ± 2.666.20 ± 2.610.3520.726Stigma6.56 ± 4.266.68 ± 4.356.44 ± 4.250.2640.793Social support2.64 ± 2.382.55 ± 2.532.72 ± 2.27−0.3430.732Cognition9.11 ± 2.039.10 ± 2.109.12 ± 2.00−0.0500.960Communication1.30 ± 1.541.36 ± 1.551.23 ± 1.550.3990.691Bodily discomfort2.27 ± 1.492.19 ± 1.572.34 ± 1.43−0.4800.632LYG Laughter yoga group, CG Control group Comparison of outcomes between the groups at pre-intervention LYG Laughter yoga group, CG Control group At post-intervention, the HAMA and HAMD scores were significantly lower in the LYG than in the CG; the difference in PDSS score was not significant; and the PDQ-39 total score was significantly lower in the LYG than in the CG, with significant differences in emotional well-being, stigma, social support, and communication and non-significant differences in mobility, activities of daily of living, cognition, and bodily discomfort (Table 2). Table 2Comparison of outcomes between the groups at post-interventionTests (mean ± SD)SUM (N = 90)LYG (n = 44)CG (n = 46)t P HAMA14.48 ± 4.1513.48 ± 3.8515.43 ± 4.25−2.2870.025HAMD8.02 ± 4.347.09 ± 4.398.91 ± 4.15−2.0260.046PDSS119.96 ± 11.19120.77 ± 10.55119.17 ± 11.830.6760.501PDQ-3930.49 ± 9.7425.70 ± 9.1735.07 ± 7.97−5.180<0.001Mobility5.50 ± 3.045.52 ± 3.615.48 ± 2.410.0680.946Activities of daily of living2.30 ± 2.382.02 ± 2.502.57 ± 2.25−1.0830.282Emotional well-being4.79 ± 2.203.36 ± 1.596.15 ± 1.81−7.751<0.001Stigma3.89 ± 3.561.68 ± 2.186.00 ± 3.34−7.298<0.001Social support1.96 ± 2.231.45 ± 2.122.43 ± 2.26−2.1220.037Cognition9.01 ± 1.999.07 ± 1.968.96 ± 2.040.2640.792Communication0.96 ± 1.310.66 ± 0.911.24 ± 1.55−2.1720.033Bodily discomfort2.09 ± 1.271.93 ± 1.262.24 ± 1.27−1.1510.253LYG Laughter yoga group, CG Control group Comparison of outcomes between the groups at post-intervention LYG Laughter yoga group, CG Control group In the LYG, the HAMA and HAMD scores were significantly lower after the intervention than before the intervention; the difference in PDSS score was not significant; and the PDQ-39 total score was significantly lower after the intervention than before the intervention, with significant differences in emotional well-being, stigma, social support, and communication and non-significant differences in mobility, activities of daily of living, cognition, and bodily discomfort (Table 3). Table 3Comparison of outcomes in the LYG before and after interventionTests (mean ± SD)SUM (N = 91)Pre-intervention in LYG (n = 47)Post-intervention in LYG (n = 44)t P HAMA15.15 ± 4.1616.72 ± 3.8513.48 ± 3.854.018<0.001HAMD8.10 ± 4.549.04 ± 4.537.09 ± 4.392.0870.040PDSS119.76 ± 11.37118.81 ± 12.13120.77 ± 10.55−0.8220.413PDQ-3931.13 ± 11.2636.21 ± 10.7225.70 ± 9.175.001<0.001Mobility5.67 ± 3.645.81 ± 3.715.52 ± 3.610.3720.711Activities of daily of living2.10 ± 2.562.17 ± 2.632.02 ± 2.500.2740.785Emotional well-being4.91 ± 2.686.36 ± 2.693.36 ± 1.596.525<0.001Stigma4.25 ± 4.306.66 ± 4.421.68 ± 2.186.876<0.001Social support2.01 ± 2.402.53 ± 2.541.45 ± 2.122.1870.031Cognition9.11 ± 2.04 9.15 ± 2.149.07 ± 1.960.1880.852Communication1.01 ± 1.331.34 ± 1.560.66 ± 0.912.5570.013Bodily discomfort2.07 ± 1.432.19 ± 1.571.93 ± 1.260.8650.389LYG Laughter yoga group, CG Control group Comparison of outcomes in the LYG before and after intervention LYG Laughter yoga group, CG Control group There were no significant differences in HAMA, HAMD, PDSS, PDQ-39, or dimensional scores between pre- and post-intervention in the CG (Table 4). Table 4Comparison of outcomes in the CG before and after interventionTests (mean ± SD)SUM (N = 93)Pre-intervention in CG (n = 47)Post-intervention in CG (n = 46)t P HAMA16.14 ± 4.3516.83 ± 4.3715.43 ± 4.251.560.122HAMD9.13 ± 4.289.34 ± 4.438.91 ± 4.150.480.632PDSS118.87 ± 12.22118.57 ± 12.71119.17 ± 11.83−0.2350.814PDQ-3935.65 ± 9.8836.21 ± 11.5135.07 ± 7.970.5580.578Mobility5.56 ± 3.325.64 ± 4.055.48 ± 2.410.2320.817Activities of daily of living2.60 ± 2.592.64 ± 2.912.57 ± 2.250.1360.892Emotional well-being6.16 ± 2.256.17 ± 2.636.15 ± 1.810.0390.969Stigma6.19 ± 3.836.38 ± 4.286.00 ± 3.340.4820.631Social support2.58 ± 2.262.72 ± 2.272.43 ± 2.250.6140.540Cognition9.03 ± 2.029.11 ± 2.018.96 ± 2.040.3560.722Communication1.24 ± 1.541.23 ± 1.551.24 ± 1.55−0.0160.987Bodily discomfort2.28 ± 1.342.32 ± 1.422.24 ± 1.270.2870.775LYG Laughter yoga group, CG Control group Comparison of outcomes in the CG before and after intervention LYG Laughter yoga group, CG Control group Among the participants, 79.55% were very satisfied with the overall intervention program, 20.45% were satisfied with the protocol, and none were dissatisfied or very dissatisfied. In the safety analysis, no adverse events were observed in either group throughout the study. Discussion Summary Laughter yoga can improve anxiety and depression symptoms in people with PD and enhance their quality of life, which has clinical and popularization significance. Effect on anxiety and depression The present study indicates that laughter yoga can significantly improve symptoms of anxiety and depression in people with PD, similar to previous studies [30–32]. This may be owing to the following reasons. First, laughter can reduce the secretion of neuroendocrine stress-related hormones by affecting the central nervous system, thereby relieving guilt and pain and increasing pleasure [33]. The pathogenesis of PD accompanied by anxiety and depression may be related to abnormal changes in neurotransmitters [34–36]. Laughter yoga enables people with PD to change their levels of metabolites by simulating laughter, thereby alleviating the symptoms of anxiety and depression in these patients. Second, laughter can promote positive emotions in individuals [37]. According to the broaden-and-build theory [27], positive emotions are conducive to enhancing the individual’s instantaneous thinking and behavior ability, and which powerful spiritual power in turn helps the individual to build lasting physical, intellectual, social, and psychological resources. people with PD are more likely to have negative emotions, such as anxiety and depression, owing to the physical discomfort caused by the disease. Laughter yoga can stimulate pleasure in people with PD by simulating laughter and promoting the production of positive emotions. Optimistic and positive life attitudes promote communication between people with PD and others, increasing their interpersonal interactions, expanding their social communication, reducing their sense of social isolation, and improving their social adaptability. Impact on sleep quality The results of this study demonstrated that laughter yoga had no significant effect on the sleep quality of people with PD. It may be primarily attributed to the complex and multifactorial nature of sleep disorders in PD, which could override the potential effects of laughter yoga. The central tissue structure of people with PD changes, which may lead to sleep disorders due to damage to the sleep-wake cycle [38]. Additionally, the nocturnal motor symptoms and autonomic nervous dysfunction caused by the disease reduce sleep quality [39]. Moreover, nonmotor symptoms, such as anxiety and depression in people with PD included in this study, and the effect of anti-PD drugs on the central nervous system aggravate sleep disorders in people with PD. These factors collectively create a robust barrier to sleep improvement—one that may not be sufficiently mitigated by laughter yoga. Furthermore, the 8-week intervention duration and intensity of laughter yoga may have been inadequate to counteract such ingrained, multifactorial sleep disturbances in PD, resulting in the lack of statistically significant changes observed. However, the PDSS score in the LYG showed a certain improvement compared to the CG after the trial, indicating that laughter yoga is a potential approach to improving sleep in people with PD. Effect on the quality of life In this study, the PDQ-39 total score was significantly lower in the LYG than in the CG. This indicates that laughter yoga improves the quality of life of people with PD, which is similar to previous studies [40]. The scores of four dimensions (emotional well-being, stigma, social support, and communication) were significantly lower in the LYG than in the CG (P < 0.05). This may be owing to the effects of simulated laughter to reduce mental stress by activating metabolic product activity and those of meditation relaxation to relax the muscles and improve the energy and mental health of patients [41]. Additionally, group exercise increases interaction among people with PD, helps to create a positive emotional state, and promotes patients’ return to society [32]. However, although the scores for mobility, activities of daily living, cognition, and bodily discomfort were lower in the LYG than in the CG in this study, there was no significant difference between the groups (P > 0.05). This may be because these dimensions are linked to other quality of life factors. A higher H-Y rating is associated with a higher PDQ-39 score and poorer quality of life [42]. The longer the course of the disease, the more severe the symptoms of people with PD and worse their quality of life [43]. Regarding disease types, the fall risk of postural instability and gait difficulty (PIGD) and non-PIGD subtypes increases with the development of PD, and patients with early, middle, and late PIGD subtypes of PD with the same disease course have a higher risk of falling and worse quality of life than those with non-PIGD subtypes [44]. Some factors did not differ between groups at baseline, but their high prevalence and impact on quality of life across the entire sample may have created a “noise floor” that masked any subtle effects of the intervention. The complexity of PD heterogeneity is a potential barrier to detecting significant outcomes. Limitations Owing to time, manpower, and geographical limitations, this study only recruited subjects from a public hospital, and the enrolled subjects were all patients with mild-to-moderate PD who could take care of themselves, which limited the generalizability of the results. Additionally, owing to financial constraints and ethical concerns, only scales were used to assess outcomes, and long-term effects were not observed. In future studies, the measurement of dopamine, serotonin, and other indicators will be considered, and the long-term effects will be discussed to improve the objectivity and persuasiveness of the study. Conclusions In this study, a laughter yoga intervention program was developed based on the broaden-and-build theory according to the characteristics of people with PD and references to relevant books. A program for people with PD with anxiety or depression was adopted as an intervention. Laughter yoga was conducive to improving the anxiety and depression symptoms of people with PD, thereby improving their quality of life and providing new ideas and methods for related nursing interventions. Supplementary Information Supplementary Material 1. Acknowledgements We thank all participants who cooperated in this trial, and thank everyone for their hard work. Abbreviations Parkinson’s disease Modified Hoehn & Yahr grading scale Unified Parkinson’s Disease Rating Scale score Hamilton anxiety scale Hamilton depression scale Parkinson’s disease sleep scale Parkinson’s disease quality of life scale-39 Laughter yoga group Control group Standard deviation Appendix 1 Table 5Laughter Yoga exercise intervention program for people with PD with anxiety or depressionItemContent01 FormGroup exercise + Autonomous exercise02 CycleEight weeks03 FrequencyGroup exerciseTwice/weekAutonomous exerciseFive times/week04 Duration20 min/time05 SiteGroup exerciseIn hospitalAutonomous exerciseIndependent choice06 Safety assessmentPre-exercise(a) Patient with PD feels good, no fever and other discomfort; (b) The heart rate is 55–100 times/min, and the blood oxygen is above 95%; (c) The patient is able to complete daily activities 1 h after taking the medication.During the exercise(a) When the exercise center rate exceeds 15%–20% of the basic value, or the blood oxygen saturation is less than 95%, stop the exercise, and continue to exercise after the vital signs are stable; (b) If dizziness, nausea, dyspnea, chest tightness or other symptoms occur, stop exercising immediately.After exerciseAfter stopping exercise on the day to the next day before exercise, if body joint pain, fatigue, or other discomfort symptoms, stop exercise and report to the researcher.07 Course contentWarm-up exerciseClaps and HO-HA. Clap in a 1–2, 1–2-3 rhythm, while the belly sounds “HO, HO, HA-HA-HA.”Rub your ear and laughThe thumb and forefinger of both hands hold both ears, do the action of rubbing up and down, rub the ears hot, and then emit “HA-HA-HA” laughter.Greeting laughHold out your hand, shake hands, maintain eye contact, and give a “HA-HA-HA” laugh.Rocking laughHands clenched, thumb out, open 45 degrees, like pouring wine, from the right hand to the left hand, and then from the left hand to the right hand, make a “hey” sound, look up and give a “HA-HA-HA” laugh.Laughing like drinking soup (Hot-soup laugh)Both hands raised to the chest to shake hard, seeming to be drinking hot soup, with a hand fanning the mouth, laughing.Bow-drawing laughBoth hands do the action of pulling a bow and arrow, giving the “Yi” sound, and finally the hands open, look up, and laugh.Laughing while counting on fingersStarting with the thumb, the left hand counts the fingers of the right hand in turn, and the right hand counts the fingers of the left hand in turn, laughing for each count.Belly laughImagine you have just heard a really funny joke, and you cannot stop laughing, with your hands over your belly.Maitreya Buddha laughCross your hands, put them on the pubic region, slowly lift your hands up to inhale, when you reach your chest, turn your palms over until you reach the top of your head, slowly open your hands, and make a “HA-HA-HA” sound at the same time.Breathing meditation(a) Take a comfortable meditation sitting position and relax the whole body; (b) Abdominal breathing, full attention to the breathing and the body at the moment feeling; (c) Focus your attention and notice how your mind fluctuates; (d) Return all of your attention to the breath.08 Note(a) 1 day before the team exercise and 2 h before the exercise call to remind participants to arrive at the exercise place on time.(b) Make sure the patient’s electronic devices are silent during team sports. Laughter Yoga exercise intervention program for people with PD with anxiety or depression (a) 1 day before the team exercise and 2 h before the exercise call to remind participants to arrive at the exercise place on time. (b) Make sure the patient’s electronic devices are silent during team sports. Appendix 2 Table 6Comparison of characteristics at baseline between two groupsCharacteristicsSUM (N = 94)LYG (n = 47)CG (n = 47)t/χ2 P Age (years), (mean ± SD)71. 19 ± 6.7871.28 ± 6.2071. 11 ± 7.390. 1210.904aSex, n (%) Male67 (71.28)34 (72.34)33 (70.21)0.0520.820bFemale27 (28.72)13 (27.66)14 (29.79)Education level, n (%) Illiteracy36 (38.30)18 (38.30)18 (38.30)0.0910.993bPrimary school31 (32.98)15 (31.91)16 (34.04)Secondary school17 (18.09)9 (19. 15)8 (17.02)Higher education10 (10.64)5 (10.64)5 (10.64)Current work status, n (%) Employed3 (3. 19)1 (2. 13)2 (4.26)< 0.001> 0.999bRetired91 (96.81)46 (97.87)45 (95.74)Marital status, n (%) Married73 (77.66)38 (80.85)35 (74.47)> 0.999cDivorced1 (1.06)0 (0.00)1 (2. 13)Widowed20 (21.28)9 (19. 15)11 (23.40)Mode of residence, n (%) Solitary9 (9.57)4 (8.51)5 (10.64)< 0.001> 0.999bNon-solitary85 (90.43)43 (91.49)42 (89.36)Per capita monthly household income(USD), n (%)136.54–409.2071 (75.53)36 (76.60)35 (74.47)0.0580.810b409.34–808.4023 (24.47)11 (23.40)12 (25.53)Mode of payment for medical care, n (%)Employee medical insurance2 (2. 13)1 (2. 13)1 (2. 13)< 0.001> 0.999bNew rural cooperative medical insurance92 (97.87)46 (97.87)46 (97.87)Number of falls in 1 year, n (%) None75 (79.79)37 (78.72)38 (80.85)> 0.999c1 fall17 (18.09)9 (19. 15)8 (17.02)2 falls2 (2. 13)1 (2. 13)1 (2. 13)Disease duration, (mean ± SD)4.87 ± 2.314.89 ± 2.194.85 ± 2.450.0890.929aNumber of comorbidities, n (%) None20 (21.28)10 (21.28)10 (21.28)0.000> 0.999b152 (55.32)26 (55.32)26 (55.32)≥ 222 (23.40)11 (23.40)11 (23.40)Modified Hoehn and Yahr stage (H-Y), (mean ± SD)1.9 ± 0.571.86 ± 0.511.95 ± 0.63−0.7230.472aUPDRSⅢ, (mean ± SD)19. 15 ± 7.3919.26 ± 7.4419.04 ± 7.420.1390.890aLevodopa equivalent dosage, (mean ± SD)552. 18 ± 236.16551.99 ± 225.26552.37 ± 251.45−0.080.990aLYG laughter yoga group, CG control group, SD standard deviation, UPDRSIII Unified Parkinson's Disease Rating Scaleat-testbChi-square test cFisher’s exact test Comparison of characteristics at baseline between two groups Per capita monthly household income (USD), n (%) Mode of payment for medical care, n (%) Employee medical insurance LYG laughter yoga group, CG control group, SD standard deviation, UPDRSIII Unified Parkinson's Disease Rating Scale at-test bChi-square test cFisher’s exact test Appendix 3 Table 7Comparison of characteristics after intervention between two groupsCharacteristicsSUM (N = 90)LYG (n = 44)CG (n = 46)t/χ2 P Age (years), (mean ± SD)71.31 ± 6.8971.43 ± 6.3371.20 ± 7.440.1620.872aSex, n (%) Male65 (72.20)32 (72.70)33 (71.70)0.0110.917bFemale25 (27.80)12 (27.30)13 (28.30)Education level, n (%) Illiteracy35 (38.90)17 (38.60)18 (39. 10)0.1860.980bPrimary school28 (31.10)13 (29.50)15 (32.60)Secondary school17 (18.90)9 (20.50)8 (17.40)Higher education10 (11.10)5 (11.40)5 (10.90)Current work status, n (%) Employed3 (3.30)1 (2.30)2 (4.30)< 0.001> 0.999bRetired87 (96.70)43 (97.70)44 (95.70)Marital status, n (%) Married70 (77.80)36 (81.80)34 (73.90)0.550cDivorced1 (1.10)0 (0.00)1 (2.20)Widowed19 (21. 10)8 (18.20)11 (23.90)Mode of residence, n (%) Solitary8 (8.90)3 (6.80)5 (10.90)0.0930.761bNon-solitary82 (91. 1)41 (93.20)41 (89. 10)Per capita monthly household income(USD), n (%)136.54–409.2068 (75.60)33 (75.00)35 (76. 10)0.0140.905b409.34–808.4022 (24.40)11 (25.00)11 (23.90)Mode of payment for medical care, n (%)Employee medical insurance2 (2.20)1 (2.30)1 (2.20)> 0.999cNew rural cooperative medical insurance88 (97.80)43 (97.70)45 (97.80)Number of falls in 1 year, n (%) None73 (81.10)35 (79.50)38 (82.60)0.890c1 fall15 (16.70)8 (18.20)7 (15.20)2 falls2 (2.20)1 (2.30)1 (2.20)Disease duration, (mean ± SD)4.82 ± 2.344.80 ± 2.204.85 ± 2.48−0.1060.916aNumber of comorbidities, n (%) None19 (21. 10)9 (20.50)10 (21.70)0.0290.986b149 (54.40)24 (54.50)25 (54.30)≥ 222 (24.40)11 (25.00)11 (23.90)Modified Hoehn and Yahr stage (H-Y), (mean ± SD)1.89 ± 0.561.83 ± 0.471.95 ± 0.63−0.9830.328aUPDRSⅢ, (mean ± SD)18.96 ± 7.4518.86 ± 7.4819.04 ± 7.51−0. 1140.910aLevodopa equivalent dosage, (mean ± SD)546.13 ± 238.99539.53 ± 224.69552.45 ± 254.23−0.2550.799aLYG laughter yoga group, CG control group, SD standard deviation, UPDRSIII Unified Parkinson's Disease Rating Scaleat-testbChi-square testcFisher’s exact test Comparison of characteristics after intervention between two groups Per capita monthly household income (USD), n (%) Mode of payment for medical care, n (%) Employee medical insurance LYG laughter yoga group, CG control group, SD standard deviation, UPDRSIII Unified Parkinson's Disease Rating Scale at-test bChi-square test cFisher’s exact test Authors’ contributions QX, XN, and YP contributed the most to this study. QX wrote and revised the manuscript with the help of XN, YP, LZ, SZ, SL, and CX. CX and XN contributed to the supervision of QX. CX was the main supervisor and corresponding author of this study. All authors read and approved the final manuscript. Funding This study was supported by National Key R&D Program of China (No.2020YFC2008500) and Key Program of Fujian Health College (No.JG2024603). Data availability The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethics Committee of a hospital in Fujian Province, China (2021KY180), and registered in the China Clinical Trial Registry (ChiCTR2200060401). Our study was in compliance with the Helsinki Declaration. All participants provided written informed consent. Consent for publication This manuscript contains only anonymized data. The participants provided consent for the publication of these data. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Qingnv Xu and Xiaoyun Nian contributed equally to this work. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.